238 related articles for article (PubMed ID: 36791846)
21. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
[TBL] [Abstract][Full Text] [Related]
22. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H
Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987
[TBL] [Abstract][Full Text] [Related]
23. Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir.
Yan D; Yan B
Fundam Clin Pharmacol; 2023 Aug; 37(4):726-738. PubMed ID: 36931725
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
[TBL] [Abstract][Full Text] [Related]
25. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models.
Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK
Nat Commun; 2023 Aug; 14(1):4731. PubMed ID: 37550333
[TBL] [Abstract][Full Text] [Related]
26. Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir.
Paciaroni A; Libera V; Ripanti F; Orecchini A; Petrillo C; Francisci D; Schiaroli E; Sabbatini S; Gidari A; Bianconi E; Macchiarulo A; Hussain R; Silvestrini L; Moretti P; Belhaj N; Vercelli M; Roque Y; Mariani P; Comez L; Spinozzi F
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047038
[TBL] [Abstract][Full Text] [Related]
27. Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability.
Gao S; Song L; Sylvester K; Mercorelli B; Loregian A; Toth K; Weiße RH; Useini A; Sträter N; Yang M; Ye B; Tollefson AE; Müller CE; Liu X; Zhan P
J Med Chem; 2023 Dec; 66(23):16426-16440. PubMed ID: 37992202
[TBL] [Abstract][Full Text] [Related]
28. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
Siniavin AE; Gushchin VA; Shastina NS; Darnotuk ES; Luyksaar SI; Russu LI; Inshakova AM; Shidlovskaya EV; Vasina DV; Kuznetsova NA; Savina DM; Zorkov ID; Dolzhikova IV; Sheremet AB; Logunov DY; Zigangirova NA; Gintsburg AL
Antiviral Res; 2024 May; 225():105871. PubMed ID: 38555022
[TBL] [Abstract][Full Text] [Related]
29. Interferon regulatory factor 3 mediates effective antiviral responses to human coronavirus 229E and OC43 infection.
Duncan JKS; Xu D; Licursi M; Joyce MA; Saffran HA; Liu K; Gohda J; Tyrrell DL; Kawaguchi Y; Hirasawa K
Front Immunol; 2023; 14():930086. PubMed ID: 37197656
[TBL] [Abstract][Full Text] [Related]
30. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].
Reina J; Iglesias C
Rev Esp Quimioter; 2022 Jun; 35(3):236-240. PubMed ID: 35183067
[TBL] [Abstract][Full Text] [Related]
31. The antiviral potential of the antiandrogen enzalutamide and the viral-androgen signaling interplay in seasonal coronaviruses.
Ogunjinmi OD; Abdullahi T; Somji RA; Bevan CL; Barclay WS; Temperton N; Brooke GN; Giotis ES
J Med Virol; 2024 Mar; 96(3):e29540. PubMed ID: 38529542
[TBL] [Abstract][Full Text] [Related]
32. An overview on the seven pathogenic human coronaviruses.
Kesheh MM; Hosseini P; Soltani S; Zandi M
Rev Med Virol; 2022 Mar; 32(2):e2282. PubMed ID: 34339073
[TBL] [Abstract][Full Text] [Related]
33. In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library.
Shahhamzehei N; Abdelfatah S; Efferth T
Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337106
[TBL] [Abstract][Full Text] [Related]
34. Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2.
Francis ME; Jansen EB; Yourkowski A; Selim A; Swan CL; MacPhee BK; Thivierge B; Buchanan R; Lavender KJ; Darbellay J; Rogers MB; Lew J; Gerdts V; Falzarano D; Skowronski DM; Sjaarda C; Kelvin AA
Nat Commun; 2023 Sep; 14(1):5990. PubMed ID: 37752151
[TBL] [Abstract][Full Text] [Related]
35. Antivirals for Broader Coverage against Human Coronaviruses.
Outteridge M; Nunn CM; Devine K; Patel B; McLean GR
Viruses; 2024 Jan; 16(1):. PubMed ID: 38275966
[TBL] [Abstract][Full Text] [Related]
36. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
[TBL] [Abstract][Full Text] [Related]
37. Incomplete IgG avidity maturation after seasonal coronavirus infections.
Struck F; Schreiner P; Staschik E; Wochinz-Richter K; Schulz S; Soutschek E; Motz M; Bauer G
J Med Virol; 2022 Jan; 94(1):186-196. PubMed ID: 34427932
[TBL] [Abstract][Full Text] [Related]
38. Interactions between seasonal human coronaviruses and implications for the SARS-CoV-2 pandemic: A retrospective study in Stockholm, Sweden, 2009-2020.
Dyrdak R; Hodcroft EB; Wahlund M; Neher RA; Albert J
J Clin Virol; 2021 Mar; 136():104754. PubMed ID: 33601153
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
Jeong JH; Chokkakula S; Min SC; Kim BK; Choi WS; Oh S; Yun YS; Kang DH; Lee OJ; Kim EG; Choi JH; Lee JY; Choi YK; Baek YH; Song MS
Antiviral Res; 2022 Dec; 208():105430. PubMed ID: 36209984
[TBL] [Abstract][Full Text] [Related]
40. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
